Toxicity of adjuvant high-dose interferon-alpha-2b in patients with cutaneous melanoma at high risk of recurrence.

1999 ◽  
Author(s):  
J Schachter ◽  
B Brenner ◽  
E Fenig ◽  
J Yahav ◽  
G Marshak ◽  
...  
Keyword(s):  
High Risk ◽  
Interferon Alpha ◽  
Cutaneous Melanoma ◽  
High Dose ◽  
Risk Of Recurrence ◽  
Interferon Alpha 2B ◽  
High Dose Interferon

scholarly journals Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials

2015 ◽  
Vol 5 (1) ◽  
pp. 17-23 ◽  
Author(s):  
Agnieszka Malczewski ◽  
Andrea Marshall ◽  
Miranda J. Payne ◽  
Lili Mao ◽  
Dimitrios Bafaloukos ◽  
...  
Keyword(s):  
High Risk ◽  
Maintenance Treatment ◽  
Meta Analysis ◽  
High Dose ◽  
Risk Of Recurrence ◽  
High Dose Interferon

scholarly journals A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma

2011 ◽  
Vol 34 (6) ◽  
pp. 509-515 ◽  
Author(s):  
Valerie P. Grignol ◽  
Thomas Olencki ◽  
Kiran Relekar ◽  
Cynthia Taylor ◽  
Amanda Kibler ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Interferon Alpha ◽  
High Dose ◽  
Phase 2 ◽  
Interferon Alpha 2B ◽  
Phase 2 Trial ◽  
High Dose Interferon

scholarly journals Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice

1999 ◽  
Vol 80 (11) ◽  
pp. 1767-1769 ◽  
Author(s):  
A Ravaud ◽  
C Bedane ◽  
L Geoffrois ◽  
T Lesimple ◽  
M Delaunay
Keyword(s):  
Interferon Alpha ◽  
High Dose ◽  
Interferon Alpha 2B ◽  
High Dose Interferon

Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence

2014 ◽  
Vol 32 (3) ◽  
pp. 185-190 ◽  
Author(s):  
Miranda J. Payne ◽  
Katerina Argyropoulou ◽  
Paul Lorigan ◽  
James J. McAleer ◽  
David Farrugia ◽  
...  
Keyword(s):  
Overall Survival ◽  
Pilot Study ◽  
High Risk ◽  
Interferon Alfa ◽  
Phase Iii ◽  
High Dose ◽  
Risk Of Recurrence ◽  
To Receive ◽  
High Dose Interferon

Purpose High-dose interferon alfa-2b (HDI) has emerged as a potentially effective adjuvant therapy in patients with resected melanoma at high risk of recurrence. Evidence suggests it may be the early, very-high-dose part of the regimen that is critical. This pilot study sought to provide an early indication of whether the same effects can be achieved with the intravenous component of HDI alone and inform the feasibility and design of a phase III trial. Patients and Methods Patients with stage 2B, 2C, 3B, and 3C melanoma were randomly assigned to receive interferon alfa-2b (IFN-α-2b) 20 MIU/m2 intravenously (IV) daily 5 days per week for 4 weeks (arm A) versus the same regimen followed by IFN-α-2b 10 MIU/m2 administered subcutaneously three times per week for 48 weeks (arm B) and observed for relapse-free survival (RFS) and overall survival. Results Between 2003 and 2009, 194 patients were enrolled (arm A, 96; arm B, 98). After median follow-up of 39.5 months, RFS was 22.7 months (95% CI, 14.1 to 38.1 months) in arm A versus 33.3 months (95% CI, 18.2 to not reached) in arm B (P = .28). The proportions of patients free of relapse at 2 years were 50% and 54.1% (P = .569; hazard ratio, 0.89), respectively. Overall survival favored arm B (median, 41.5 months v not reached; P = .05). Conclusion Clinical outcomes were better in patients who had the longer regimen. Our results do not support either the use of a month of IV HDI alone in place of the year-long regimen or the initiation of a larger trial on this question.

Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 8524-8524 ◽  
Author(s):  
A. A. Tarhini ◽  
S. J. Moschos ◽  
H. Tawbi ◽  
Y. Shuai ◽  
W. E. Gooding ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Interferon Alpha ◽  
Phase Ii ◽  
High Dose ◽  
Interferon Alpha 2B ◽  
High Dose Interferon

A phase II randomized study of adjuvant imatinib versus high-dose interferon alpha-2b for resected high-risk c-kit mutated melanoma.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e20027-e20027
Author(s):  
Lu Si ◽  
Xuan Wang ◽  
Yan Kong ◽  
Bin Lian ◽  
Zhi Hong Chi ◽  
...  
Keyword(s):  
High Risk ◽  
Adjuvant Therapy ◽  
Randomized Study ◽  
Growth Factor Receptor ◽  
High Dose ◽  
Interferon Alpha 2B ◽  
Risk Melanoma ◽  
Exon 11 ◽  
One Year ◽  
High Dose Interferon

e20027 Background: Imatinib, a selective inhibitor targeting Abl as well as C-Kit and the platelet-derived growth factor receptor, has been tested for the efficacy and toxicities in metastatic melanoma patients harboring mutations in C-Kit gene. High-dose interferon for one year (HDI) is the FDA approved adjuvant therapy for patients (pts) with high-risk melanoma. This study (NCT01782508) aims to see whether imatinib is more effective than interferon alfa-2b in adjuvant therapy for patients with C-Kit mutated melanomas. Methods: This study enrolled C-Kit mutated(exon 9,11 or 13)pts who were high risk (stage IIB to stage IIIC) and randomized them to receive either imatinib (400mg daily for a year) or HDI (interferon a-2b 15X106 U/m2 d1–5/wX4w + 9X106U tiwX48w) in the absence of disease progression or unacceptable toxicity. 40 pts of each group were planned to enroll. Routine tests including blood tests, medical history updates, physical exams and Brain/Chest/Abdomen/Pelvic CT were performed every 2 months. The endpoints were recurrence-free survival (RFS) and overall survival. Results: Through Jan 2013,7 pts were recruited F3 in imatinib arm and 4 in HDI arm. The three pts received imatinib haven’t had recurrence or metastasis. The RFS were 6m+ (Exon 11: W577S), 5m+ (Exon 11: L576P), 5m+ (Exon 11: L576P) respectively. Two pts have already had lung or regional lymphnode at 4 months (Exon 13: K642E) and 5 months (Exon 11: V560D) in the HDI arm. The other two pts (both Exon 11: 579 insert) in the HDI arm were still disease free for 6 months. The toxicities were consistent with the usual reported studies. Conclusions: In the C-Kit mutated melanoma pts, it’s promising that imatinib may provide more beneficial effect than HDI for high-risk melanomas. (Supported by the National Natural Science Foundation of China (30973483, 81172196, 81102068.) Clinical trial information: NCT01782508.

Sign in / Sign up

Export Citation Format

Share Document